Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Veracyte, Inc. - Common Stock (NQ:VCYT)

31.99 -0.47 (-1.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte Inc (NASDAQ:VCYT) Emerges as a Strong Value Pick with Solid Fundamentals and Growth Potential
Veracyte (VCYT) emerges as a potential value stock with strong valuation, profitability, and growth metrics in the biotech sector, backed by solid financial health and cash flow potential. 
Via Chartmill
Veracyte (VCYT) Q2 Revenue Jumps 14%
Via The Motley Fool
Veracyte Announces Second Quarter 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics
Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation. 
Via Benzinga
VERACYTE INC (NASDAQ:VCYT) – An Undervalued Stock with Strong Fundamentals
VERACYTE INC (NASDAQ:VCYT) is an undervalued biotech stock with strong financial health, solid profitability, and impressive growth prospects, making it a candidate for value investors. 
Via Chartmill
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
From Veracyte, Inc.
Via Business Wire
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
From Veracyte, Inc.
Via Business Wire
Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet
 
Via Benzinga
Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems
Ark Invest made notable trades on Friday, including purchasing shares of Veracyte Inc. and selling shares of 3D Systems Corp. 
Via Benzinga
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
From Veracyte, Inc.
Via Business Wire
VERACYTE INC (NASDAQ:VCYT) – A Promising Affordable Growth Stock in Biotechnology
VERACYTE INC (NASDAQ:VCYT) is a biotechnology stock with strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth... 
Via Chartmill
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Breaking Down Veracyte: 7 Analysts Share Their Views
 
Via Benzinga
Veracyte Announces First Quarter 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch
Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch 
Via Chartmill
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms
ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details. 
Via Benzinga
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
From Veracyte, Inc.
Via Business Wire
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences. 
Via Investor's Business Daily
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
From Veracyte, Inc.
Via Business Wire
Despite its growth, VERACYTE INC (NASDAQ:VCYT) remains within the realm of affordability.
Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
From Veracyte, Inc.
Via Business Wire
While growth is established for VERACYTE INC (NASDAQ:VCYT), the stock's valuation remains reasonable.
NASDAQ:VCYT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.